Observational studyRespiratory research2022
Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study.
Observational study in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03131362 (REALizing and Improving Management of Stable COPD in China--A Multi-centre, Prospective, Observational Study to Realize the Current Situation of COPD Patients in China.), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
REALizing and Improving Management of Stable COPD in China--A Multi-centre, Prospective, Observational Study to Realize the Current Situation of COPD Patients in China.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of non-smoking chronic obstructive pulmonary disease and its risk factors in China: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- COPD Patients with a High Exacerbation Risk: Baseline Data Analysis of a National Chinese Prospective Multi-Center Study of Quality Improvement Project.International journal of chronic obstructive pulmonary disease · 2026Trial
- COPD burden trends in China and G20 countries from GBD 2023 and Mendelian randomization.iScience · 2026Article
- Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study.Advances in therapy · 2026Article
- Efficacy and safety of TQC3403 in patients with chronic obstructive pulmonary disease (COPD): a multicenter, randomized, open-label, phase 3 equivalence trial.Journal of thoracic disease · 2026Article
- Identification of key influencing factors of health information literacy in COPD patients: a cross-sectional study using a random forest model.BMC pulmonary medicine · 2026Article
- Patterns and Adherence to GOLD-Recommended Inhaled Therapy in Chronic Obstructive Pulmonary Disease (COPD) Patients with Acute Exacerbation History in Primary Care in China.International journal of chronic obstructive pulmonary disease · 2026Article
- Gender Divergence in COPD Phenotypes and Narrowing Urban-Rural Diagnostic Gaps: A Surveillance Study in Chongqing, China, 2020-2024.International journal of chronic obstructive pulmonary disease · 2026Article
- Divergent roles of serum CXCL9 as a biomarker in ILD and COPD: a comparative study.Frontiers in pharmacology · 2026Article
- Identification of genetic variants of theAnnals of medicine · 2025Article
- Time to Death and Its Predictor Among Outpatients With COPD: A Retrospective Cohort Study in Northwestern Ethiopia.Health science reports · 2025Article
- Cost-effectiveness of chronic obstructive pulmonary disease population screening in China: based on individual data from WHO Collaborating Centre-initiated 'Enjoying Breathing Program'.BMC public health · 2025Article
- Defining a non-eosinophilic inflammatory subtype in COPD: the role of CXCL9 and type 1 immune responses.Frontiers in immunology · 2025Article
- How Does Disease Severity Affect Clinical Outcomes and Economic Burden of Patients with COPD -- A Retrospective Population-Based Cohort Study in Tianjin, China.International journal of chronic obstructive pulmonary disease · 2025Article
- A Qualitative Study on Illness Perception and Coping Behaviors Among Patients with Chronic Obstructive Pulmonary Disease: Implications for Intervention.International journal of chronic obstructive pulmonary disease · 2024Article
- Hospitalization costs of COPD cases and its associated factors: an observational study at two large public tertiary hospitals in Henan Province, China.BMC geriatrics · 2023Observational
- The Impact of the GOLD 2023 on Clinical Treatment in Northeast China.International journal of chronic obstructive pulmonary disease · 2023Article
- Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment.Mediators of inflammation · 2023Review
- Correction to: Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study.Respiratory research · 2022Article
- Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).Therapeutic advances in respiratory diseaseObservational
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) receives low awareness and is undertreated in China. Understanding the burden and treatment of COPD across the nation is important for improving quality of care for this disease. This study aims to reveal the current situation of COPD severity distribution and management across China.
methodsBaseline data from REALizing and Improving Management of Stable COPD in China, a multicentre, prospective, longitudinal, observational study, were analysed. Patients diagnosed with COPD as per Global Initiative for Chronic Obstructive Lung Disease 2016 (GOLD 2016) criteria were enrolled from 50 randomly selected hospitals (tertiary, 25; secondary, 25) across six geographical regions. Data were collected in routine clinical settings.
resultsBetween 15 December 2017 and 6 August 2020, 5013 patients were enrolled and 4978 included in the full analysis set. Of these, 2459 (49.4%) reported ≥ 1 exacerbation within 12 months prior to study enrolment, with a mean annual rate of 0.9/patient, including 0.2/patient and 0.5/patient leading to emergency room visits and hospitalisation, respectively. Spirometry graded 458 (10.1%), 1886 (41.7%), 1558 (34.5%), and 616 (13.6%) were GOLD stage I-IV, and 536 (11.4%), 1034 (22.0%), 563 (12.0%), and 2566 (54.6%) were classified as GOLD 2016 Group A-D, respectively, without evident regional variations. Inhaled corticosteroids plus long-acting beta
conclusionsDisease burden among Chinese COPD outpatients is high. Improved guideline adherence for COPD treatment is needed. Trial registration ClinicalTrials.gov identifier, NCT03131362.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.